GSK, Jemperli

GSK’s Cancer Drug Jemperli Moves a Step Closer to European Marketing Permission
In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...
GSK's Cancer Drug Jemperli Nears EU Marketing Expansion -- 2nd Update
GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the pharmaceutical giant's oncology pipeline.
GSK的Jemperli获得FDA突破性疗法认定用于治疗直肠癌
Jemperli是一种抗PD-1抗体，是GSK免疫肿瘤学研究和开发的基础。它目前在美国获批用于某些类型的子宫内膜癌，并在加速批准下用于dMMR复发或晚期实体瘤，继续批准取决于确证性试验的验证。本报告基于GSK plc的新闻稿。